The Icahn School of Medicine at Mount Sinai (Icahn Mount Sinai) in New York City is pleased to announce that CastleVax, Inc., has completed enrollment and a preliminary analysis of a phase 1 trial of its licensed Newcastle disease virus (NDV)-based COVID-19 booster vaccine.
NEW YORK, July 13, 2023 /PRNewswire-PRWeb/ -- The Icahn School of Medicine at Mount Sinai (Icahn Mount Sinai) in New York City is pleased to announce that CastleVax, Inc., has completed enrollment and a preliminary analysis of a phase 1 trial of its licensed Newcastle disease virus (NDV)-based COVID-19 booster vaccine.
The phase 1 study evaluated two dose levels of the live, recombinant vaccine, NDV-HXP-Spike(S), delivered intranasally, intramuscularly, or via both routes in combination, in participants previously vaccinated with an authorized intramuscular COVID-19 vaccine.
Interim results show that intranasal delivery resulted in a robust S-specific, secretory IgA response in saliva relative to pre-booster levels, which is important for conferring mucosal immunity and has the potential to prevent infection and/or transmission of COVID-19. In addition, a strong boosting of serum neutralizing-antibody response was observed, which is important for conferring systemic immunity and prevention of severe disease, hospitalization, and death (the efficacy endpoint(s) for currently authorized intramuscularly delivered vaccines). The safety profile was also acceptable, successfully clearing the Data Safety Monitoring Board reviews.
"We are thrilled with the progress led by principal investigator Sean Liu, MD, PhD, and our Mount Sinai colleagues, and are both excited and encouraged by these preliminary results," said Michael Egan, PhD, CastleVax Chief Scientific Officer and acting Chief Executive Officer. "Dr. Liu's preliminary findings complement those of our development partners in Mexico, Avimex, whose interim phase 3 results showed their live, attenuated NDV-based vaccine (Patria® (AVX/COVID-12), licensed from CastleVax, was effective as a booster against COVID-19."
"The initial observations from our phase 1 trial of NDV-HXP-S as a COVID-19 booster vaccination suggest that it is safe and well-tolerated when delivered intranasally and/or intramuscularly to healthy adults. The preliminary exploratory findings looking at mucosal and systemic antibody responses are encouraging, particularly when NDV-HXP-S is administered intranasally. There is a growing interest in developing vaccines that not only protect against the severe illnesses caused by respiratory pathogens but also limit host susceptibility and decrease person-to-person transmissions by enhancing the mucosal immune response. I am excited to watch as the NDV-vectored vaccine platform matures to address newer variants of concern in larger randomized controlled trials," said Sean Liu, MD, PhD, Assistant Professor of Medicine (Infectious Diseases, and Hospital Medicine) at the Icahn School of Medicine at Mount Sinai.
The NDV-vectored vaccine platform was developed by Peter Palese, PhD, Horace W. Goldsmith Professor and Chair of Microbiology; Adolfo García-Sastre, PhD, Irene and Dr. Arthur M. Fishberg Professor of Medicine and Director of the Global Health and Emerging Pathogens Institute; and Florian Krammer, PhD, Professor of Microbiology, and Pathology, Molecular and Cell Based Medicine, at Icahn Mount Sinai, and was licensed by Mount Sinai to CastleVax Inc. Mount Sinai has a financial interest in this technology and in CastleVax. Drs. Palese, García-Sastre, and Krammer, and Weina Sun, PhD, Assistant Professor of Microbiology, also have a financial interest in this technology and in CastleVax pursuant to the Mount Sinai Intellectual Property Policy. Mount Sinai is represented on the CastleVax Board of Directors by Erik Lium, PhD, Chief Commercial Innovation Officer, Mount Sinai Health System, and President, Mount Sinai Innovation Partners; Dennis S. Charney, MD, Anne and Joel Ehrenkranz Dean of Icahn Mount Sinai and President for Academic Affairs of the Mount Sinai Health System; Matthew Rosamond, Chief Financial Officer, Icahn Mount Sinai; and Stephen Harvey, MBA, Chief Financial Officer, Mount Sinai Health System. The phase 1 trial mentioned above is led by independent faculty investigators (Dr. Liu and Judith A. Aberg, MD, Chief of the Division of Infectious Diseases, Mount Sinai Health System) who have no financial interests in the vaccine or with CastleVax.
About NDV-HXP-S: The NDV-based vaccine technology was developed at Icahn Mount Sinai in the laboratories of Drs. Palese, García-Sastre, and Krammer. HexaPro (HXP) was developed at UT Austin.
About CastleVax
In August 2022, the Mount Sinai Health System launched CastleVax, Inc., a clinical-stage vaccine research and development company devoted to the commercial development of the NDV vaccine platform technology.
For more information on CastleVax and the NDV vaccine platform, visit https://www.castlevax.com.
About the Mount Sinai Health System
Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with more than 43,000 employees working across eight hospitals, over 400 outpatient practices, nearly 300 labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time — discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it. Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients' medical and emotional needs at the center of all treatment. The Health System includes approximately 7,300 primary and specialty care physicians; 13 joint-venture outpatient surgery centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and more than 30 affiliated community health centers. For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.
About the Icahn School of Medicine at Mount Sinai
The Icahn School of Medicine at Mount Sinai is internationally renowned for its outstanding research, educational, and clinical care programs. It is the sole academic partner for the eight member hospitals* of the Mount Sinai Health System, one of the largest academic health systems in the United States, providing care to a large and diverse patient population.
Ranked 14th nationwide in National Institutes of Health (NIH) funding and among the 99th percentile in research dollars per investigator according to the Association of American Medical Colleges, Icahn Mount Sinai has a talented, productive, and successful faculty. More than 3,000 full-time scientists, educators and clinicians work within and across 34 academic departments and 35 multidisciplinary institutes, a structure that facilitates tremendous collaboration and synergy. Our emphasis on translational research and therapeutics is evident in such diverse areas as genomics/big data, virology, neuroscience, cardiology, geriatrics, as well as gastrointestinal and liver diseases.
Icahn Mount Sinai offers highly competitive MD, PhD, and Master's degree programs, with current enrollment of approximately 1,300 students. It has the largest graduate medical education program in the country, with more than 2,000 clinical residents and fellows training throughout the Health System. In addition, more than 550 postdoctoral research fellows are in training within the Health System.
The Icahn School of Medicine at Mount Sinai is located in New York City on the border between the Upper East Side and East Harlem and classroom teaching takes place on a campus facing Central Park. Icahn Mount Sinai's location offers many opportunities to interact with and care for diverse communities. Learning extends well beyond the borders of our physical campus, to the eight hospitals of the Mount Sinai Health System, our academic affiliates, and globally.
Media Contact
Elizabeth Dowling, Mount Sinai Health System, 212-241-9200, [email protected]
Twitter
SOURCE Icahn School of Medicine at Mount Sinai
Advertisement
NEW YORK, July 13, 2023 /PRNewswire-PRWeb/ -- The Icahn School of Medicine at Mount Sinai (Icahn Mount Sinai) in New York City is pleased to announce that CastleVax, Inc., has completed enrollment and a preliminary analysis of a phase 1 trial of its licensed Newcastle disease virus (NDV)-based COVID-19 booster vaccine.
Advertisement
The phase 1 study evaluated two dose levels of the live, recombinant vaccine, NDV-HXP-Spike(S), delivered intranasally, intramuscularly, or via both routes in combination, in participants previously vaccinated with an authorized intramuscular COVID-19 vaccine.
Interim results show that intranasal delivery resulted in a robust S-specific, secretory IgA response in saliva relative to pre-booster levels, which is important for conferring mucosal immunity and has the potential to prevent infection and/or transmission of COVID-19. In addition, a strong boosting of serum neutralizing-antibody response was observed, which is important for conferring systemic immunity and prevention of severe disease, hospitalization, and death (the efficacy endpoint(s) for currently authorized intramuscularly delivered vaccines). The safety profile was also acceptable, successfully clearing the Data Safety Monitoring Board reviews.
"We are thrilled with the progress led by principal investigator Sean Liu, MD, PhD, and our Mount Sinai colleagues, and are both excited and encouraged by these preliminary results," said Michael Egan, PhD, CastleVax Chief Scientific Officer and acting Chief Executive Officer. "Dr. Liu's preliminary findings complement those of our development partners in Mexico, Avimex, whose interim phase 3 results showed their live, attenuated NDV-based vaccine (Patria® (AVX/COVID-12), licensed from CastleVax, was effective as a booster against COVID-19."
"The initial observations from our phase 1 trial of NDV-HXP-S as a COVID-19 booster vaccination suggest that it is safe and well-tolerated when delivered intranasally and/or intramuscularly to healthy adults. The preliminary exploratory findings looking at mucosal and systemic antibody responses are encouraging, particularly when NDV-HXP-S is administered intranasally. There is a growing interest in developing vaccines that not only protect against the severe illnesses caused by respiratory pathogens but also limit host susceptibility and decrease person-to-person transmissions by enhancing the mucosal immune response. I am excited to watch as the NDV-vectored vaccine platform matures to address newer variants of concern in larger randomized controlled trials," said Sean Liu, MD, PhD, Assistant Professor of Medicine (Infectious Diseases, and Hospital Medicine) at the Icahn School of Medicine at Mount Sinai.
The NDV-vectored vaccine platform was developed by Peter Palese, PhD, Horace W. Goldsmith Professor and Chair of Microbiology; Adolfo García-Sastre, PhD, Irene and Dr. Arthur M. Fishberg Professor of Medicine and Director of the Global Health and Emerging Pathogens Institute; and Florian Krammer, PhD, Professor of Microbiology, and Pathology, Molecular and Cell Based Medicine, at Icahn Mount Sinai, and was licensed by Mount Sinai to CastleVax Inc. Mount Sinai has a financial interest in this technology and in CastleVax. Drs. Palese, García-Sastre, and Krammer, and Weina Sun, PhD, Assistant Professor of Microbiology, also have a financial interest in this technology and in CastleVax pursuant to the Mount Sinai Intellectual Property Policy. Mount Sinai is represented on the CastleVax Board of Directors by Erik Lium, PhD, Chief Commercial Innovation Officer, Mount Sinai Health System, and President, Mount Sinai Innovation Partners; Dennis S. Charney, MD, Anne and Joel Ehrenkranz Dean of Icahn Mount Sinai and President for Academic Affairs of the Mount Sinai Health System; Matthew Rosamond, Chief Financial Officer, Icahn Mount Sinai; and Stephen Harvey, MBA, Chief Financial Officer, Mount Sinai Health System. The phase 1 trial mentioned above is led by independent faculty investigators (Dr. Liu and Judith A. Aberg, MD, Chief of the Division of Infectious Diseases, Mount Sinai Health System) who have no financial interests in the vaccine or with CastleVax.
About NDV-HXP-S: The NDV-based vaccine technology was developed at Icahn Mount Sinai in the laboratories of Drs. Palese, García-Sastre, and Krammer. HexaPro (HXP) was developed at UT Austin.
About CastleVax
In August 2022, the Mount Sinai Health System launched CastleVax, Inc., a clinical-stage vaccine research and development company devoted to the commercial development of the NDV vaccine platform technology.
For more information on CastleVax and the NDV vaccine platform, visit https://www.castlevax.com.
About the Mount Sinai Health System
Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with more than 43,000 employees working across eight hospitals, over 400 outpatient practices, nearly 300 labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time — discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it. Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients' medical and emotional needs at the center of all treatment. The Health System includes approximately 7,300 primary and specialty care physicians; 13 joint-venture outpatient surgery centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and more than 30 affiliated community health centers. For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.
About the Icahn School of Medicine at Mount Sinai
The Icahn School of Medicine at Mount Sinai is internationally renowned for its outstanding research, educational, and clinical care programs. It is the sole academic partner for the eight member hospitals* of the Mount Sinai Health System, one of the largest academic health systems in the United States, providing care to a large and diverse patient population.
Ranked 14th nationwide in National Institutes of Health (NIH) funding and among the 99th percentile in research dollars per investigator according to the Association of American Medical Colleges, Icahn Mount Sinai has a talented, productive, and successful faculty. More than 3,000 full-time scientists, educators and clinicians work within and across 34 academic departments and 35 multidisciplinary institutes, a structure that facilitates tremendous collaboration and synergy. Our emphasis on translational research and therapeutics is evident in such diverse areas as genomics/big data, virology, neuroscience, cardiology, geriatrics, as well as gastrointestinal and liver diseases.
Icahn Mount Sinai offers highly competitive MD, PhD, and Master's degree programs, with current enrollment of approximately 1,300 students. It has the largest graduate medical education program in the country, with more than 2,000 clinical residents and fellows training throughout the Health System. In addition, more than 550 postdoctoral research fellows are in training within the Health System.
The Icahn School of Medicine at Mount Sinai is located in New York City on the border between the Upper East Side and East Harlem and classroom teaching takes place on a campus facing Central Park. Icahn Mount Sinai's location offers many opportunities to interact with and care for diverse communities. Learning extends well beyond the borders of our physical campus, to the eight hospitals of the Mount Sinai Health System, our academic affiliates, and globally.
Media Contact
Elizabeth Dowling, Mount Sinai Health System, 212-241-9200, [email protected]
SOURCE Icahn School of Medicine at Mount Sinai
